BioSpace News Archive

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, reported financial results for the second quarter ended June 30, 2021.

Kadmon Holdings, Inc. announced that the National Comprehensive Cancer Network® added REZUROCKTM tablets to its NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its second quarter 2021 financial results after the market closes on Tuesday, August 10, 2021.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2021 and updated its sales guidance for the year ending December 31, 2021.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a general business update.

AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced second quarter 2021 financial results.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, reported unaudited financial results for the quarter ended June 30, 2021.

Reported net sales increased 15.1% to $225.9 million, and constant currency net sales increased 7.8%, reflecting growth across all product categories.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conferences in August: